Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo shows promise against tough cancers

NCT ID NCT05516914

Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, LBL-007 and tislelizumab, in 98 adults with advanced solid tumors. The goal was to see if the combo is safe, tolerable, and effective at shrinking tumors. Researchers also looked at how the drugs move through the body and whether they trigger an immune response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LBL-007 combined with tislelizumab (and sometimes chemotherapy drugs like cisplatin, gemcitabine, or docetaxel)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that are hard to treat.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 98 participants, so results may not apply broadly. Side effects from combining these drugs are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

98 people

The number who actually took part.

Started

Sep 2022

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Agree to follow the experimental treatment plan and visit plan, join the group voluntarily, and sign a written informed consent form; 2. Age ≥ 18 and ≤ 75 years old when signing the informed consent form, regardless of gender; 3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) PS is 0\~1; 4. The expected survival time is at least 12 weeks; 5. According to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1), the subjects enrolled have at least one measurable tumor lesion; 6. Subject has adequate organ and bone marrow function 7. Males with fertility and females of childbearing age are willing to take effective contraceptive measures (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception from the signing of the informed consent form to 6 months after the last administration of the trial drug Sets, etc.); women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered. Exclusion Criteria: 1. Have received other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time; 2. Those who have clinically uncontrollable pleural effusion, pericardial effusion or ascites, requiring repeated drainage or medical intervention; 3. Women during pregnancy or lactation; 4. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study. 5. Patients with history of severe cardiovascular and cerebrovascular diseases. 6. Patients with active infection and currently requiring intravenous anti-infective treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant tumors

Contacts and locations

Locations

  • Anhui Cancer Hospital

    Hefei, Anhui, 230031, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350001, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, 530000, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430000, China

  • Huizhou Municipal Central Hospital

    Huizhou, Guangdong, 516000, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410000, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, 330029, China

  • Sun Yat-Sen Memorial Hospital，Sun Yat-Sen University

    Guangzhou, Guangdong, 510120, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021, China

  • The First People's Hospital of Yu Lin

    Yulin, Guangxi, 537000, China

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, 570000, China

  • Union Hospital Tongji Medical College Huazhong University of Science And Technology

    Wuhan, Hubei, 430022, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

  • Zhejiang Cancer Hospital

    Hangzhou, Hangzhou, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.